Neovascular age-related macular degeneration (nAMD)

• Phase IIIb Study of 36-Week Refill Exchanges of Port Delivery System with Ranibizumab in nAMD Recruiting
  2024-516924-32-00 5 2025-10-17
• A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Recruitment ended
  2023-507131-38-00 5 2022-05-16
• A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients … Recruitment ended
  2023-507130-24-00 5 2021-10-22
• A study to learn about the blood levels of aflibercept when high-dose aflibercept is injected in both eyes of participants with diabetic mac … Ended
  2024-511665-11-00 6 2024-08-29
• A Clinical Trial to compare Efficacy, Safety, Tolerability of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneratio … Ended
  2023-509206-29-00 5

Showing 1–5 of 5 trials